Automate Your Wheel Strategy on PGEN
With Tiblio's Option Bot, you can configure your own wheel strategy including PGEN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PGEN
- Rev/Share 0.0146
- Book/Share -0.0199
- PB -34.3351
- Debt/Equity -0.1401
- CurrentRatio 2.7058
- ROIC -1.2579
- MktCap 1269364980.0
- FreeCF/Share -0.23
- PFCF -18.6157
- PE -10.1431
- Debt/Assets 0.0506
- DivYield 0
- ROE -4.9412
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | PGEN | JP Morgan | Underweight | Neutral | -- | -- | Aug. 15, 2025 |
News
PGEN Stock Surges 144% in August on FDA Nod for Rare Lung Disease Drug
Published: August 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Precigen stock soars 144% in August after FDA approval of Papzimeos, the first treatment for adults with recurrent respiratory papillomatosis.
Read More
Undercovered Dozen: Precigen, ONEOK, Bitmine And More
Published: August 22, 2025 by: Seeking Alpha
Sentiment: Positive
This week's Undercovered Dozen highlights 12 lesser-known stocks and ETFs with compelling investment theses and recent catalysts. Standouts include CGDV's market-beating performance, DIVO's retirement risk management, and ONEOK's undervaluation and growth prospects. Speculative opportunities like Viking Therapeutics and Gorilla Technology offer high risk/reward, while Canadian Natural Resources and Rheinmetall present strong value and growth.
Read More
Precigen: This Billion-Dollar Approval Is Still Undervalued
Published: August 15, 2025 by: Seeking Alpha
Sentiment: Positive
PAPZIMEOS's full FDA approval for RRP is a decisive, de-risking event and validates Precigen's immunotherapy platform. PAPZIMEOS targets a significant unmet need, with potential for $1B+ peak sales, though logistical hurdles and launch friction exist. Precigen faces imminent financing needs due to limited cash runway and increased burn from its first commercial launch.
Read More
Precigen, Inc. (PGEN) Q4 2024 Earnings Call Transcript
Published: March 19, 2025 by: Seeking Alpha
Sentiment: Neutral
Precigen, Inc. (NASDAQ:PGEN ) Q4 2024 Earnings Conference Call March 19, 2025 4:30 PM ET Company Participants Steven Harasym - IR Helen Sabzevari - President and CEO Rutul Shah - COO Phil Tennant - CCO Harry Thomasian - CFO Conference Call Participants Jason Butler - Citizens Carolina Ibanez Ventoso - Stifel Swayampakula Ramakanth - H.C. Wainwright Jennifer Kim - Cantor Brian Cheng - JPMorgan Operator Good evening, and welcome to the Precigen's Full Year 2024 Financial Results and Business Update Call.
Read More
Precigen, Inc. (PGEN) Reports Q4 Loss, Lags Revenue Estimates
Published: March 19, 2025 by: Zacks Investment Research
Sentiment: Negative
Precigen, Inc. (PGEN) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to loss of $0.09 per share a year ago.
Read More
Precigen: UltraCAR-T Development Brings Another Side Of Pipeline Advancement
Published: February 28, 2025 by: Seeking Alpha
Sentiment: Positive
BLA of PRGN-2012 for patients with Recurrent Respiratory Papillomatosis was accepted by FDA with a Priority Review date of August 27th of 2025. Marketing approval of PRGN-2012 for RRP would be huge because there is no FDA approved drugs for RRP. Also, there are an estimated 27,000 people in the United States who have it. PGEN is looking to form a strategic partnership or collaboration agreement to advance its UltraCAR-Ts. This technology is crucial because it could change CAR-T landscape for the better.
Read More
Precigen, Inc. (PGEN) Just Flashed Golden Cross Signal: Do You Buy?
Published: February 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Precigen, Inc. (PGEN) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, PGEN's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.
Read More
About Precigen, Inc. (PGEN)
- IPO Date 2013-08-08
- Website https://www.precigen.com
- Industry Biotechnology
- CEO Helen Sabzevari MPH,
- Employees 143